JAK2 and myeloproliferative disorder: Importantly, oncogenic mutation of JAK2 in myeloproliferative neoplasms was recently shown to induce surface PD-L1 expression through increased promotor activity, and this transformation of myeloid cells was associated with a reduction of T-cell metabolic activity and proliferation [57].